Vitrectomy using precise fluid movement

Article

Breaking news from the floor of ESCRS

With fluidics in modern vitrectomy one of the continuing hot topics in ophthalmology Oertli's focus at this year's ESCRS was its Faros fluidics system which, using the peristaltic principle allows doctors to exercise precision regulation. The compact device allows immediate vacuum build-up, which can be precisely controlled using the system's foot pedal. The pump also enables control of aspiration flow and can control micro-flow rates in the range of 1 mL so that there are no effects as a result of peristaltic rolls. Additionally, the system includes the easyPhaco technology for 2.2 and 1.6 mm micro incision surgery.

Peristaltic pumps work with flow by means of roller systems. Compression of the tubes by the rotating movement 'milks' the liquid column out of the tubing system. While this is happening the flow can be directly controlled. The preset vacuum is achieved as soon as the outflow is occluded, i.e. As a rule, at the tip of the cutter. As soon as occlusion occurs, the vacuum starts building up, the rollers begin to move more slowly and the outflow decreases. How quickly the rollers respond can partly be influenced by how this parameter is present.

Oertli has recently undertaken a great deal of research looking at two pump concepts, flow controlled and vacuum controlled, or peristaltic and venture. Visit www.oertl-instruments.com for more information.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.